Pegaspargase
From Wikipedia, the free encyclopedia
Pegaspargase
|
|
Systematic (IUPAC) name | |
Pegylated E. coli L-asparagine amidohydrolase | |
Identifiers | |
CAS number | |
ATC code | L01 |
PubChem | ? |
DrugBank | |
Chemical data | |
Formula | C1377H2208N382O442S17 |
Mol. mass | 31731.9 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Pegaspargase is an antineoplastic agent.
It is used in the treatment of acute lymphoblastic leukemia.[1]
It is a form of L-asparaginase[2] which has undergone PEGylation.
[edit] References
- ^ Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. PMID 14499708.
- ^ UNM Cancer Center. Retrieved on 2007-08-28.